Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743426 · ClinicalTrials.gov registry record
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
A clinical trial of Sarcoma and Gastrointestinal Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 180
- Enrollment target
- 1
- Study location
NCT05743426: Recruiting study of Sarcoma and Gastrointestinal Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT05743426 is a study of Sarcoma and Gastrointestinal Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 180 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743426, a study of Sarcoma and Gastrointestinal Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.
Primary Outcome
Disease-free survival is defined as the length of time after treatment in which the subject survives with no signs or symptoms of cancer.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Toxicity Assessments
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill, Department of Radiation Oncology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2036-01-01 |
What NCT05743426 shows while recruiting
NCT05743426 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Survey is the first listed.
NCT05743426 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05743426 about?
NCT05743426 is a clinical study titled "Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies". This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches ...
What is the current status of trial NCT05743426?
This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2023-03-17. Estimated completion is 2036-01-01.
What conditions does trial NCT05743426 study?
This clinical trial studies the following conditions: Sarcoma, Gastrointestinal Cancer.
What interventions are being tested in trial NCT05743426?
The interventions under investigation include: Survey (OTHER), Toxicity Assessments (OTHER).
Who is sponsoring clinical trial NCT05743426?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743426 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05743426's enrollment target sits among peer trials
180 31st of 122 higher than 92 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy